PUORRO, GIORGIA
 Distribuzione geografica
Continente #
NA - Nord America 402
EU - Europa 185
AS - Asia 113
AF - Africa 6
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 711
Nazione #
US - Stati Uniti d'America 396
IT - Italia 76
SG - Singapore 57
DE - Germania 44
CN - Cina 38
NL - Olanda 26
IN - India 14
IE - Irlanda 8
FI - Finlandia 7
FR - Francia 7
GB - Regno Unito 7
CI - Costa d'Avorio 6
CA - Canada 5
VN - Vietnam 4
BR - Brasile 3
BE - Belgio 2
ES - Italia 2
RU - Federazione Russa 2
BZ - Belize 1
CL - Cile 1
EU - Europa 1
LT - Lituania 1
PT - Portogallo 1
RS - Serbia 1
SE - Svezia 1
Totale 711
Città #
Chandler 112
Singapore 48
Santa Clara 42
Ashburn 31
Amsterdam 26
Millbury 15
Nanjing 13
Pune 13
Beijing 11
Des Moines 10
Milan 9
Naples 8
Princeton 8
Lawrence 7
Le Cannet 7
Boston 6
Dearborn 6
Leawood 5
Seattle 5
Dong Ket 4
Acerra 3
Davis 3
Los Angeles 3
Napoli 3
Ottawa 3
Wilmington 3
Brussels 2
Changchun 2
Dublin 2
Formia 2
Guangzhou 2
Helsinki 2
Kronberg 2
Latina 2
London 2
Madrid 2
Marano di Napoli 2
Munich 2
Phoenix 2
Portici 2
Rome 2
Sant'arpino 2
Toronto 2
Torre Annunziata 2
Washington 2
Whitby 2
Albuquerque 1
Atlanta 1
Belize City 1
Buffalo 1
Cagliari 1
Caserta 1
Dallas 1
Esslingen am Neckar 1
Fairfield 1
Falkenstein 1
Hefei 1
High Point 1
Houston 1
Jacksonville 1
Jiaxing 1
Jinan 1
Las Vegas 1
Moscow 1
Mumbai 1
Nanchang 1
Nola 1
Norwalk 1
Nuremberg 1
Nürnberg 1
Qinhuangdao 1
Rio De Janeiro 1
Saint Louis 1
San Jose 1
Santiago 1
São Paulo 1
Tianjin 1
Torino 1
Woodbridge 1
Xian 1
Yingkou 1
Totale 479
Nome #
Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. 70
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study 66
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 63
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 63
Peripheral markers of autophagy in polyglutamine diseases 46
Stability of erythropoietin repackaging in polypropylene syringes for clinical use 44
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis 44
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab 43
Mobitz type I and II atrioventricular blocks during fingolimod therapy 42
Consistent improvement with eculizumab across muscle groups in myasthenia gravis 36
Eculizumab improves fatigue in refractory generalized myasthenia gravis 35
Increased endothelin-1 serum levels in patients with multiple sclerosis 34
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis 34
Correction to: Peripheral markers of autophagy in polyglutamine diseases (Neurological Sciences, (2018), 39, 1, (149-152), 10.1007/s10072-017-3156-6) 26
Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia 26
The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients 25
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial 21
Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich Ataxia (DMF-FA-201) 19
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension 17
Totale 754
Categoria #
all - tutte 3.384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.384


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202026 0 0 0 0 0 2 8 3 2 5 6 0
2020/202138 8 1 4 2 7 1 3 1 2 3 1 5
2021/202285 3 0 3 1 0 2 3 4 8 10 10 41
2022/2023219 19 34 1 22 24 27 1 19 30 28 10 4
2023/2024136 1 14 11 6 7 30 1 17 3 7 28 11
2024/2025140 28 18 6 17 29 42 0 0 0 0 0 0
Totale 754